The DEA cliff is 4 months away

The fourth temporary extension, published at the end of last December, lets clinicians keep prescribing Schedule II through V controlled substances by telehealth without an in-person visit. It runs out in about four months.

The replacement on the table is the special registration proposed rule, which would cap telehealth at an initial 30-day supply for Schedule III-V before an in-person evaluation is required to continue.

That rule is not final and may never be. But testosterone is Schedule III, and this is the fourth extension in a row, which is not a pattern that suggests permanence.

If you sell TRT, HRT or anything scheduled, this is the single biggest structural risk to your retention numbers in 2027 and almost nobody is building for it.

One-year persistence among patients without diabetes has climbed from 33.2% in 2021 to 60.9% in the first half of 2024, per an analysis in the Journal of Managed Care & Specialty Pharmacy.

Better dose escalation and side effect management get most of the credit, along with the end of the shortage era.

The number nearly doubled in three years. Any retention benchmark you set before 2024 is describing a different market.

On August 13, investors in Wondermind filed a federal securities fraud suit alleging the company misrepresented its growth trajectory, the involvement of its celebrity co-founder, and the readiness of products that never shipped. The company disputes the claims and has said it will move to dismiss.

Set aside the celebrity angle and the pattern is ordinary: a health brand whose story ran further ahead of its delivery than it could sustain.

The gap between what acquisition promises and what onboarding delivers is a retention problem long before it becomes a legal one.

Every telehealth brand built on controlled substances has a retention event with a date on it, and the date is December 31.

Most operators are treating this as a compliance question for their legal counsel.

It is a lifecycle question, and the flow it requires does not exist in a single TRT brand we have looked at.

Federal flexibilities let you prescribe testosterone after a video visit. They lapse at the end of December unless DEA extends a fifth time or finalises something.

The proposed replacement would give a new patient 30 days by telehealth, then require an in-person evaluation before you can continue.

Read that as a lifecycle spec rather than a legal one. It inserts a mandatory, high-friction, offline step between the first refill and the second.

In this category the first weeks are where patients are lost. Side effects are peaking, results have not arrived, and commitment is at its thinnest.

Now put "find a clinic, book an appointment, take time off work, physically go" into that window.

You would be asking for the largest effort of the entire patient relationship at the precise moment the patient is least convinced it is worth it. If the rule lands as proposed, month two stops being a retention problem and becomes a logistics problem you have never had to solve.

Telehealth lifecycle programs are built to keep people out of clinics. The entire value proposition is the absence of that step.

Which means there is no template for this. There is no in-person handoff sequence, no appointment-booking reminder cadence, no reschedule recovery, no "you missed your visit and your prescription lapses in nine days" save.

Those are all standard flows in categories that do have physical appointments, and none of them are in your ESP right now.

There is also no data model for it. Most telehealth CRMs have no field for appointment booked, appointment attended, or appointment missed, because those events have never existed in the funnel. You cannot build a save sequence around a status you do not track.

Takeaway: treat this as a contingency build, not a prediction. Spend a few hours drafting the in-person handoff flow and park it unlaunched. If DEA extends again you lost an afternoon. If the rule lands in December, you are the brand that already has the sequence while your competitors are writing it in January with their month-two cohort walking out the door.

One-year GLP-1 persistence went from 33.2% to 60.9% in three years. If your board deck still cites the old "most patients quit within a year" framing, you are measuring against a market that stopped existing.

The practical consequence is worse than an out-of-date slide. Targets set against 2021 persistence make a mediocre program look like it is outperforming.

Re-baseline against current-era data before you decide which flows are working.

New Jersey ended its state-level flexibility for telehealth prescribing of Schedule II controlled substances back in February, while the federal flexibilities still run. States are diverging, and they will keep diverging after December.

Most lifecycle programs treat the US as one market. Your flows send the same refill reminder to a patient in a state where the refill is legal and one where it is not.

State is not a personalisation field in this category. It is a suppression field, and it needs to be on your controlled-substance flows before the rules fragment further.

Pull a list of every active patient on a controlled substance, segmented by state.

That single list tells you the size of your exposure, and most operators have never actually looked at it as one number.

Then draft two emails and leave them unpublished.

The first explains what is changing and what you are doing about it, (sent from the provider rather than the brand). The second is the booking prompt: here is why the visit is required, here is how to find a clinic, here is what happens to your prescription if you do not.

Takes an afternoon. If the rule never lands, you have wasted one. If it does, you start December with the sequence already written instead of finding out in January what a month-two cliff does to your cohort.

If retention is your biggest revenue leak, that’s what we fix. growthtrigger.xyz

Reply to this with your biggest retention challenge. I read and respond to every single one.